论文部分内容阅读
【目的】探讨重组人表皮生长因子（human epidermal grow th factor ，hEGF）凝胶联合玻璃酸钠滴眼液治疗白内障超声乳化术后干眼症的临床疗效。【方法】选取2012年1月至2014年6月于本院行白内障超声乳化手术并在术后发生干眼的200例（277眼）患者作为研究对象，随机分为两组：其中观察组100例（采用重组hEGF＋玻尿酸钠治疗），对照组100例（采用玻璃酸钠）。比较两组患者的主观症状评分的各级别例数，泪膜破裂时间（break up time of the tear film ，BUT），角膜荧光染色评分（corneal fluorescein score ，FL），基础泪液分泌试验（SchirmerI test ，SIt）和上下泪河数值。【结果】两组患者术后1 d ，1周和1个月的主观症状评分统计各级别的例数与术前比差异具有统计学意义（ P ＜0．05），观察组患者术后的主观症状评分各级别例数显著优于对照组，差异具有统计学意义（ P ＜0．05）；患者术后1 d ，1周和1个月的BU T ，SIt和FL与术前比差异具有统计学意义（ P ＜0．05），观察组患者术后的BUT ，SIT显著高于对照组，而FL显著低于对照组，差异具有统计学意义（ P ＜0．05）；患者术后1 d ，1周和1个月的U／LTMH ，U／LTMD和U／LMA与术前比差异具有统计学意义（ P ＜0．05），观察组患者术后的U／LTMH ，U／LTMD和U／LMA显著高于对照组，差异具有统计意义（ P ＜0．05）。【结论】重组hEGF凝胶联合玻璃酸钠滴眼液可以有效改善白内障术后干眼症患者的临床症状和泪膜稳定性，促进患者恢复。“,”[Objective] To explore the efficacy of recombinant human epidermal growth factor (hEGF) plus sodium hyaluronate in the treatment of xerophthalmia after cataract phacoemulsification .[Methods]From January 2012 to May 2014 ,a total of 200 patients with xerophthalmia after cataract phacoemulsification were recruited and divided into study (recombinant hEGF+ sodium hyaluronate) and control (sodium hyaluronate) groups ( n=100 each) .The subjective symptom score ,break up time of tear film (BUT) ,Schirmer I test (Sit) ,corneal fluorescein score (FL) and values of upper and lower river of tears were compared between two groups .[Results] The subjective symptom scores of all patients at 1d ,1w and 1m after surgery had statistical differences with those before surgery ( P<0 .05) .The subjective symptom scores at 1d ,1w ,1m and 3 m af‐ter surgery had inter‐group statistical differences ( P<0 .05) .BUT ,SIt and FL at 1d ,1w and 1m after sur‐gery had statistical differences with those before surgery ( P <0 .05) .And BUT ,SIt and FL at 1d ,1w ,1m and 3 m after surgery had inter‐group statistical differences ( P <0 .05) .And U/LTM H ,U/LTMD and U/LMA for all patients at 1d ,1w and 1m after surgery had statistical difference with those before surgery ( P<0 .05) .U/LTMH ,U/LTMD and U/LMA at 1d ,1w ,1m and 3 m after surgery had inter‐group statistical differences ( P < 0 .05 ) .[Conclusion] Recombinant hEGF plus sodium hyaluronate can effectively alleviate clinical symptoms and tear film stability and promote patient recovery in patients with xerophthalmia after cata‐ract phacoemulsification .